SCHEMBL294361

SCHEMBL294361

Cc1ccccc1CS(=O)(=O)O

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
ALDH1A1 P00352 3/20 0.47
GAA P10253 2/20 0.47
TAAR1 Q96RJ0 1/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
HPGD P15428 2/20 0.42
CTBP2 P56545 1/20 0.42
CHRM2 P08172 1/20 0.41
PTGS1 P23219 1/20 0.41
PTGS2 P35354 1/20 0.41
CA2 P00918 1/20 0.41
TP53 P04637 2/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4003594 0.98 LMNA (0.49) LMNAALDH1A1GAATAAR1MEN1
Fluoride SCHEMBL9120865 0.98 LMNA (0.49) LMNAALDH1A1GAATAAR1MEN1
SCHEMBL4003590 0.98 LMNA (0.49) LMNAALDH1A1GAATAAR1MEN1
SCHEMBL10939770 0.85 ESR1 (0.43) LMNAALDH1A1GAACA2TP53
SCHEMBL10398011 0.84 TSHR (0.42) LMNAALDH1A1MEN1KMT2ACA2
SCHEMBL27661203 0.83 ALDH1A1 (0.50) LMNAALDH1A1GAAKMT2AHPGD
Hydrochloric Acid SCHEMBL28259960 0.83 ESR1 (0.42) LMNAALDH1A1GAACA2TP53
SCHEMBL776517 0.82 ALDH1A1 (0.50) LMNAALDH1A1GAATAAR1MEN1
Hydrochloric Acid SCHEMBL11757162 0.81 TSHR (0.40) LMNAALDH1A1MEN1KMT2ACA2
SCHEMBL2376651 0.80 ALDH1A1 (0.49) LMNAALDH1A1GAATAAR1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7619095-B2 Process for the preparation of indolone derivative ALEMBIC LIMITED (IN) 2009-11-17 US claimed
EP-1848691-B1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LTD (IN) 2009-11-11 EP claimed
US-20080262244-A1 Process for the Preparation of Indolone Derivative ALEMBIC LIMITED (IN) 2008-10-23 US claimed
EP-1928853-A2 PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL AMR Technology, Inc. (US) 2008-06-11 EP claimed
EP-1848691-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE Alembic Limited (IN) 2007-10-31 EP claimed
WO-2007041167-A2 PROCESS FOR PRODUCTION OF DELTA-9-TETRAHYDROCANNABINOL AMR TECHNOLOGY, INC. (US) 2007-04-12 WO claimed
WO-2006123356-A1 PROCESS FOR THE PREPARATION OF INDOLONE DERIVATIVE ALEMBIC LIMITED (IN) 2006-11-23 WO claimed
EP-0255134-B1 CARBOSTYRIL DERIVATIVES AND SALTS THEREOF, PROCESS FOR PREPARING THEM, AND CARDIOTONIC COMPOSITION CONTAINING SAME OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1993-03-03 EP claimed
WO-2025136842-A1 PROCESS FOR PREPARING N-AMINOALKYLATED TRYPTOPHAN COMPOUNDS MERCK SHARP & DOHME LLC (US) 2025-06-26 WO disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-20240262834-A1 SYNTHESIS OF BTK INHIBITOR AND INTERMEDIATES THEREOF MERCK SHARP & DOHME LLC (US) 2024-08-08 US disclosed
EP-4400492-A1 ACRIDINE COMPOUND OSAKA UNIVERSITY (JP) 2024-07-17 EP disclosed
US-20240208999-A1 HETEROCYCLIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2024-06-27 US disclosed
CN-118103359-A Preparation method of eribulin derivative 江苏恒瑞医药股份有限公司 2024-05-28 CN disclosed
EP-0115334-A1 Benzo-heterocyclic compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-08-08 EP disclosed
US-4454130-A CARDIOTONIC, HYPOTENSIVE AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-06-12 US disclosed
EP-0109653-A2 Process for preparing urokinase complex OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-05-30 EP disclosed
US-4435404-A ANTICOAGULANTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1984-03-06 US disclosed
US-4415572-A CARDIOTONIC AND INOTROPIC AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1983-11-15 US disclosed
US-4139530-A CATIONIC DYES BAYER AKTIENGESELLSCHAFT (DE) 1979-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262244-A1 Process for the Preparation of Indolone Derivative HTR3C, HTR3B, HTR1B LMNA 3078/4885ALDH1A1 786/4885GAA 4401/4885
US-20240208999-A1 HETEROCYCLIC COMPOUND AHR, PDGFRA, PDGFRB LMNA 3284/4885ALDH1A1 698/4885GAA 4515/4885
US-20240262834-A1 SYNTHESIS OF BTK INHIBITOR AND INTERMEDIATES THEREOF BTK, SYK, LYN LMNA 4325/4885ALDH1A1 3569/4885GAA 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.